Table 2.
Effects of several inhibitors involved in TLR-2 signaling pathway on protein level of TNF-α, IL-6, IL-8, IL-10 and SERT in MAP-infected Caco-2 monolayers in the presence of excess level (500 ng/mL) of 5-HT following 24 h of incubation.
| Treatment | TNF-α ± SD (pg/mL) | IL-6 ± SD (pg/mL) | IL-8 ± SD (pg/mL) | IL-10 ± SD (pg/mL) | SERT ± SD (pg/mL) |
|---|---|---|---|---|---|
| Control (MAP + 500 ng/mL 5-HT) | 194.8 ± 6.3 | 185.2 ± 1.8 | 198.3 ± 1.9 | 94.3 ± 3.3 | 9.6 ± 2.6 |
| TLR-2 Inhibitor (MMG 11 (5 ng/mL)) | 82.3 ± 5.1* | 84.1 ± 1.3* | 81.9 ± 2.4* | 87.8 ± 1.4* | 22.2 ± 1.5* |
| ERK Inhibitor (PD 98059 (40 uM)) | 169.5 ± 3.7 | 172.4 ± 5.2 | 165.5 ± 6.8 | 61.4 ± 2.7 | 13.4 ± 2.4 |
| p38 MAPK Inhibitor (SB 220025 (1 uM)) | 101.2 ± 4.8* | 104.7 ± 7.9* | 97.1 ± 3.1* | 79.3 ± 1.6* | 20.1 ± 2.7* |
| cAMP/PKA Inhibitor (KT 5720 (1 uM)) | 161.9 ± 2.4 | 167.6 ± 1.4 | 158.6 ± 4.2 | 65.7 ± 3.9 | 14.4 ± 1.2 |
| 5-HT3 Receptor Antagonist (Ondansetron (40 ng/mL)) | 109.7 ± 6.1* | 112.1 ± 3.8* | 105.3 ± 1.9* | 75.1 ± 2.3* | 19.3 ± 2.6* |
Values were pre-tested for normal distribution using the Kolmogorov–Smirnov normality test. Significance among experiments was assessed by two-way analysis of variance (ANOVA) followed by Bonferroni correction test. All ELISA experiments were performed in triplicates. *P value < 0.05.